

GAU 1635  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE** Box 520

04/17/98



Applicants: Dakai Liu et al.  
Serial No. 08/822,963  
Filed: March 21, 1997  
Title: **VECTORS AND VIRAL VECTORS,  
AND PACKAGING CELL LINES  
FOR PROPOGATING SAME**

Group Art Unit: 1635

Examiner: Sean McGarry

16X  
4/23

527 Madison Avenue, 9th Floor  
New York, New York 10022  
April 17, 1998

**FILED BY EXPRESS MAIL**

Honorable Commissioner  
of Patents and Trademarks  
Washington, D.C. 20231

Attention: **Box Sequence**

RECEIVED

APR 22 1998

MAIL ROOM  
FBI - NEW YORK

**COMMUNICATION DIRECTED TO NOTICE  
TO COMPLY WITH SEQUENCE RULES**

Dear Sirs:

This Communication is directed to the Notice To Comply With Sequence rules that was attached to the Notice to File Missing Parts of Application – Filing Date Granted that was mailed on July 14, 1997 in connection with the above-identified application and subsequent Communication dated March 19, 1998. A copy of the March 19, 1998 Communication with Notice To Comply With Requirements For Patent Application Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures is attached hereto.

In response to the sequence notice, Applicants hereby submit the following documents or items:

1. A copy of the March 19, 1998 Communication with Notice To Comply With Requirements For Patent Application Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures
2. initial paper copy of the "Sequence Listing;"

ENZ-56

EXPRESS MAIL CERTIFICATE	
Express Mail® Item No.	EM36656661US
Deposit Date	April 17, 1998
I hereby certify that the paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office in Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231	
Ronald C. Fedus Reg. No. 32,567	APR 17 1998 Date

Dakai-Liu et al.

Serial No. 08/822,963

File: March 21, 1997


Page 2 (Communication Directed to Notice to Comply With Sequence Rules -  
April 17, 1998)

3. Amendment directing entry of the "Sequence Listing into the specification;
4. computer readable form (CFR) copy of the "Sequence Listing;" and
5. Declaration Under 37 C.F.R. §1.821(g) attesting that the content of the paper and computer readable copies are the same and include no new matter.

No fee is believed due in connection with this Communication or the documents or items submitted herewith. If any fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Communication, the undersigned may be contacted by telephone at (212) 583-0100 during the daytime hours.

Respectfully submitted,



Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicants

ENZO THERAPEUTICS, INC.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9<sup>th</sup> Fl.)  
New York, New York 10022  
(212) 583-0100

LC/USProsecution/Enz56/communication.re.sequence rules.10.1.97